Diligence memo · auto-generated · as of July 2, 2026
Ascella Biosystems, Inc.
Ascella Biosystems, Inc. looks fair against its niche peers and is at-risk on financing cadence.
Businessfiled
Ascella Biosystems, Inc. operates in Other Health Care, based in SAN FRANCISCO.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Ascella Biosystems, Inc. has raised $6.3M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $6.3M on 2023-12-18.
Most recent recorded round closed around 2023-12-18.
Valuation (modeled)modeled
Provath models Ascella Biosystems, Inc. at approximately $37M (range $8.1M–$90M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.01× the median modeled value of Series A Other Health Care companies in 2022–2024 (196 peers) — value vs value, same stage and era. Within the normal band (101% of peer median) for its niche.
Financing rhythm & timingmixed
Last raise 2.5 yr ago; this sector typically re-raises about every 14 months.
Past due for a raise versus sector cadence — watch for distress or a bridge.
Comparablesmixed
Capital scale ranks ahead of 69% of Other Health Care peers (5377 compared).
Modeled value ranks above 62% of those peers.
Closest niche peers: CareHarmony, Inc., Dragonfly Endoscopy Inc., NuvoAir Holdings, Inc., Post Acute Recovery, Inc., Micro Interventional Devices, Inc..
Peoplefiled
3 named people on file across officers, directors and signatories.
Risks & flagsmixed
Overdue for a raise versus sector norm — distress or bridge risk.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.